Quality of life and neutropenia in patients with early stage breast cancer: A randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone

Breast Cancer: Basic and Clinical Research

Volumn 3, Issue 1, 2009, Pages 35-45

  Tröger, Wilfried ^a   Jezdić, Svetlana ^b   Ždrale, Zdravko ^b   Tišma, Nevena ^b   Hamre, Harald J ^c   Matijašević, Miodrag ^b  

^a Clinical Research Dr Tröger   (Germany)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^c Institut fur angewandte Erkenntnistheorie und medizinische Methodologie e V   (Germany)

Author keywords

Breast cancer; Mistletoe thereapy; Neutropenia; Quality of life; Randomized clinical trial

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; ISCADOR M SPECIAL; ONDANSETRON; RANITIDINE; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; FATIGUE; FEMALE; HUMAN; INJECTION SITE REACTION; INSOMNIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; SKIN MANIFESTATION; VISCUM ALBUM;

EID: 77749232963     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/bcbcr.s2905     Document Type: Article

References (24)

1. Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst. 2004 March 3;96(5):376-387 (Pubitemid 38351299)
2. de Jong N, Candel MJ, Schouten HC, Abu-Saad HH, Courtens AM. Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol. 2004 June;15(6):896-905. (Pubitemid 39004345)
3. de Jong N, Candel MJ, Schouten HC, Abu-Saad HH, Courtens AM. Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol. 2005 March;16(3):372-382 (Pubitemid 40458312)
4. Goldstein D, Bennett B, Friedlander M, Davenport T, Hickie I, Lloyd A. Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer. 2006 October 9;6:240. (Pubitemid 44613105)
5. Kuo HH, Chiu MJ, Liao WC, Hwang SL. Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer. J Formos Med Assoc. 2006 January;105(1):64-69
6. Butt Z, Rosenbloom SK, Abernethy AP, et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw. 2008 May;6(5):448-455 (Pubitemid 351754243)
7. Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park). 2000 November; 14(11A):151-161
8. Heiny BM. Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema). Krebsmedizin. 1991;12(Sonderdruck):1-14.
9. Heusser P, Braun SB, Ziegler R, et al. Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine. Forsch Komplementarmed. 2006 April; 13(2):94-100. (Pubitemid 44014994)
10. Piao BK, Wang YX, Xie GR, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res. 2004 January;24(1):303-309
11. Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebocontrolled, double-blind, multicentre clinical trial. Anticancer Res. 2004 March;24(2C):1293-1302 (Pubitemid 38624978)
12. Semiglazov VF, Stepula VV, Dudov A, Schnitker J, Mengs U. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2006 March;26(2B):1519-1529 (Pubitemid 38624978)
13. Büssing A, Schietzel M, Regnery A, Schweizer K. The dual role of Viscum album L. effects: cytostatic and DNA stabilizing properties. Eur J Allerg Clin Immun. 1995;26:9.
14. Büssing A, Regnery A, Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett. 1995 August 1;94(2):199-205.
15. Büssing A, Jurin M, Zarkovic N, Azhari T, Schweizer K. DNA-stabilisierende Wirkungen von Viscum album L.-Sind Mistelextrakte als Adjuvans während der konventionellen Chemotherapie indiziert? Forsch Komplementärmed Klass Naturheilkd. 1996;3:244-248 (Pubitemid 126487694)
16. Auerbach L, Dostal V, Václavik-Fleck I, et al. Signifikant höherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-CA-Patientinnen in einer prospektiven randomisierten doppelblinden Studie. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editors. Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung. Essen: KCV Verlag; 2005. p. 543-554
17. Gerhard I. Problems of randomised treatment studies in complementary medicine. Forschende Komplementärmedizin 7, 34-35. 2000. Ref Type: Abstract.
18. Rostock M, Huber R. Randomized and double-blind studies-demands and reality as demonstrated by two examples of mistletoe research. Forsch Komplementarmed Klass Naturheilkd. 2004 August;11(Suppl.1):18-22. (Pubitemid 39279365)
19. Ziegler R. Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials? Evid Based Complement Alternat Med. 2007 October 4; Open Access Article, doi:10.1093/ecam/nem121:1-12. Available at: URL: PM:18955241.
20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 March 3;85(5):365-376 (Pubitemid 23073154)
21. Brunner E, Langer F. Nichtparametrische Analyse longitudinaler Daten. München: Oldenbourg Verlag; 1999.
22. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001 May 24;344(21):1594-1602 (Pubitemid 32479913)
23. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med. 2004 August;256(2):91-100. (Pubitemid 38998255)
24. Hrobjartsson A, Gotzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2004;(3):CD003974.